Analyst Ratings January 27, 2026

DA Davidson Keeps Buy on Crane, $235 Target; Earnings, Backlog and M&A Capacity Highlighted

Analyst affirms bullish view after stronger-than-expected quarters, while Crane firms up leadership succession and maintains a conservative leverage profile

By Jordan Park CR
DA Davidson Keeps Buy on Crane, $235 Target; Earnings, Backlog and M&A Capacity Highlighted
CR

DA Davidson reiterated a Buy rating on Crane (NYSE: CR) with an unchanged price target of $235 following quarterly results that outperformed its internal model. The company delivered operating EPS ahead of expectations, posted growth in core orders and backlog, completed strategic acquisitions, and outlined a planned CEO succession, while maintaining a strong liquidity and leverage position that supports further M&A activity.

Key Points

  • DA Davidson reiterated a Buy rating on Crane with a $235 price target after results outperformed the firm’s model.
  • Crane beat operating EPS expectations by $0.06, driven by core sales and margin upside in Aerospace & Electronics and Payment & Merchandising Technologies.
  • Core orders rose nearly 2% year-over-year and organic backlog increased about 15%, lifting total backlog to $1.44 billion; pro forma net debt stands at 1.4x earnings with over $1.5 billion available for M&A.

Overview

DA Davidson has maintained its Buy recommendation on Crane, assigning a $235.00 price target after the industrial products manufacturer reported results that topped the firm’s expectations. The stock is trading above its assessed Fair Value, with a quote near $198.51 and a 34.8% total return over the last year.

Earnings and segment performance

Crane reported operating earnings per share that exceeded DA Davidson’s model by $0.06. The outperformance was attributed to stronger-than-expected core sales and upside in operating profit margins across both Crane’s Aerospace & Electronics (formerly A&E) and Payment & Merchandising Technologies (PFT) segments.

Orders, backlog and revenue dynamics

The company’s core orders rose almost 2% year-over-year, while organic backlog expanded by roughly 15%, a gain driven largely by the Aerospace & Electronics segment. Total backlog now stands at $1.44 billion. Management reported core sales growth of 5.4% in the fourth quarter, supported by healthy demand in aerospace and defense end markets.

Acquisitions and balance sheet position

Crane completed the previously disclosed acquisition of PSI and an additional complementary bolt-on purchase. On a pro forma basis, net debt is approximately 1.4 times earnings, and the company reports more than $1.5 billion of capacity available for potential future mergers and acquisitions. Data cited in the release indicates Crane holds more cash than debt on its balance sheet and shows a current ratio of 3.27, underscoring a conservative liquidity profile.

Guidance and near-term outlook

The midpoint of Crane’s 2026 guidance was reported to be roughly $0.10 above DA Davidson’s comparable forecast. That slight upside in the guidance midpoint contributed to the analyst reaffirmation of a Buy opinion. Management’s commentary also flagged a slight revenue miss in recent reporting despite solid core-sales and operating-profit gains.

Quarterly results detail

For 2025, Crane reported a 23% increase in earnings per diluted share. In the fourth quarter specifically, adjusted EPS was $1.53, a 21% increase from the same period the prior year. The company also posted third-quarter adjusted EPS of $1.64, beating the $1.43 forecast and representing a 14.69% surprise versus expectations. These sequential beats highlighted the company’s margin resilience even amid a minor top-line shortfall.

Leadership transition

Crane announced a management succession plan in which Alex Alcala, currently serving as COO, is slated to assume the role of CEO in April 2026. Concurrently, current CEO Max Mitchell will transition to Executive Chairman. The planned change aligns with the company’s multi-year strategy and timing provided alongside 2026 guidance assumptions.

Analyst activity and market context

In addition to DA Davidson’s reaffirmation, Wolfe Research initiated coverage on Crane with an Outperform rating and a $215.00 price target, which Wolfe characterized as implying about 17% upside from current levels. Wolfe noted that Crane’s shares have risen about 20% year-to-date, placing the stock toward the lower end of its aerospace coverage universe.

Research and investor resources

Data referenced in the release identifies additional investor-oriented points on Crane, including its 55-year dividend payment streak and favorable return metrics. The company’s in-depth Pro Research Report and related analyses were highlighted as resources for subscribers seeking a deeper dive into the metrics behind the headline results.


Implications for sectors

  • Industrial manufacturing - Crane’s results and backlog growth reflect demand dynamics for engineered components.
  • Aerospace and defense - Outperformance was concentrated in aerospace and defense end markets, which led backlog expansion.
  • Payments and merchandising - Margin improvement in PFT contributed to the company’s operating EPS beat.

Risks

  • Slight revenue miss in recent reporting despite EPS beats - revenue weakness could pressure industrial and aerospace market expectations.
  • Leadership transition - the planned CEO succession to Alex Alcala in April 2026 introduces execution risk during a period of strategic integration and guidance realization.
  • M&A integration and capital deployment - while Crane has capacity for further acquisitions, successful integration of PSI and bolt-on deals is necessary to sustain margin and backlog momentum.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026